Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
9.50
-0.09 (-0.94%)
Nov 21, 2024, 4:00 PM EST - Market closed
Amicus Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 493.67 | 399.36 | 329.23 | 305.51 | 260.89 | 182.24 | Upgrade
|
| Revenue Growth (YoY) | 32.58% | 21.30% | 7.76% | 17.11% | 43.16% | 99.72% | Upgrade
|
| Cost of Revenue | 49.43 | 37.33 | 38.6 | 34.47 | 31.04 | 21.96 | Upgrade
|
| Gross Profit | 444.24 | 362.03 | 290.63 | 271.05 | 229.84 | 160.27 | Upgrade
|
| Selling, General & Admin | 306.95 | 275.27 | 213.04 | 192.71 | 156.41 | 169.86 | Upgrade
|
| Research & Development | 114.2 | 152.38 | 276.68 | 272.05 | 308.44 | 286.38 | Upgrade
|
| Operating Expenses | 429.84 | 435.52 | 495.06 | 470.97 | 473.7 | 461.01 | Upgrade
|
| Operating Income | 14.4 | -73.49 | -204.43 | -199.92 | -243.85 | -300.74 | Upgrade
|
| Interest Expense | -50.47 | -50.15 | -37.12 | -32.47 | -22.43 | -18.87 | Upgrade
|
| Interest & Investment Income | 5.66 | 7.08 | 3.02 | 0.51 | 3.23 | 10.25 | Upgrade
|
| Other Non Operating Income (Expenses) | -14.83 | -15.89 | 4.18 | -2.9 | -0.78 | -2.63 | Upgrade
|
| EBT Excluding Unusual Items | -45.23 | -132.45 | -234.35 | -234.78 | -263.83 | -311.99 | Upgrade
|
| Merger & Restructuring Charges | -9.19 | - | - | - | - | - | Upgrade
|
| Asset Writedown | - | -1.13 | -6.62 | - | - | - | Upgrade
|
| Other Unusual Items | -13.93 | -16.52 | -1.08 | -6.77 | -10.42 | -43.92 | Upgrade
|
| Pretax Income | -68.35 | -150.1 | -242.04 | -241.55 | -274.25 | -355.91 | Upgrade
|
| Income Tax Expense | 36.34 | 1.48 | -5.47 | 8.91 | 2.6 | 0.48 | Upgrade
|
| Net Income | -104.69 | -151.58 | -236.57 | -250.46 | -276.85 | -356.39 | Upgrade
|
| Net Income to Common | -104.69 | -151.58 | -236.57 | -250.46 | -276.85 | -356.39 | Upgrade
|
| Shares Outstanding (Basic) | 303 | 295 | 289 | 271 | 259 | 240 | Upgrade
|
| Shares Outstanding (Diluted) | 303 | 295 | 289 | 271 | 259 | 240 | Upgrade
|
| Shares Change (YoY) | 3.63% | 2.11% | 6.50% | 4.85% | 7.67% | 29.40% | Upgrade
|
| EPS (Basic) | -0.35 | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | Upgrade
|
| EPS (Diluted) | -0.35 | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | Upgrade
|
| Free Cash Flow | -31.51 | -76.53 | -170.34 | -206.38 | -236.52 | -270.43 | Upgrade
|
| Free Cash Flow Per Share | -0.10 | -0.26 | -0.59 | -0.76 | -0.91 | -1.12 | Upgrade
|
| Gross Margin | 89.99% | 90.65% | 88.28% | 88.72% | 88.10% | 87.95% | Upgrade
|
| Operating Margin | 2.92% | -18.40% | -62.09% | -65.44% | -93.47% | -165.03% | Upgrade
|
| Profit Margin | -21.21% | -37.96% | -71.85% | -81.98% | -106.12% | -195.56% | Upgrade
|
| Free Cash Flow Margin | -6.38% | -19.16% | -51.74% | -67.55% | -90.66% | -148.39% | Upgrade
|
| EBITDA | 23.09 | -65.62 | -199.08 | -193.71 | -235.01 | -295.97 | Upgrade
|
| EBITDA Margin | 4.68% | -16.43% | -60.47% | -63.40% | -90.08% | -162.41% | Upgrade
|
| D&A For EBITDA | 8.69 | 7.87 | 5.34 | 6.21 | 8.85 | 4.78 | Upgrade
|
| EBIT | 14.4 | -73.49 | -204.43 | -199.92 | -243.85 | -300.74 | Upgrade
|
| EBIT Margin | 2.92% | -18.40% | -62.09% | -65.44% | -93.47% | -165.03% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.